15 Genetic Toxicology CROs

What is genetic toxicology and when do you need it?

Genetic toxicology is the part of your IND-enabling safety work that asks a narrow but unforgiving question: can this molecule damage DNA. A genotoxic compound can cause point mutations, break or rearrange chromosomes, or change chromosome number, and any of those is a flag for carcinogenic and heritable risk. Regulators treat it as a gating safety domain, so the genotox battery is a fixed expectation in almost every small-molecule IND, and the design follows ICH S2(R1), the guideline that defines which tests count and how to interpret them.

You commission this work once you have a clinical candidate and enough drug substance to dose, in the same window as your pivotal GLP toxicology, safety pharmacology, and toxicokinetics. It does not sit on the critical path the way a six-month repeat-dose tox study does, because the in vitro assays are comparatively fast, but a positive result late in the program is one of the worse surprises in development. A clastogenic or mutagenic hit can force follow-up mechanistic work, change your starting dose conversation, or in the worst case stop the candidate. That is why many teams run a non-GLP screening version (a mini-Ames, an early in vitro micronucleus) during late lead optimization, then run the definitive GLP battery for the filing.

The battery is also where drug-substance and drug-product chemistry meets toxicology. Beyond the parent molecule, genetic toxicology is how you qualify mutagenic impurities and degradants under ICH M7, often paired with an in silico (Q)SAR assessment of structural alerts. If an impurity carries a DNA-reactive alert, you either control it below the threshold of toxicological concern or test it. Scope that conversation early, because it pulls your CMC and tox vendors into the same room.

What does a genetic toxicology CRO actually do?

A genetic toxicology CRO runs the standard ICH S2(R1) battery, almost always to GLP, and writes the reports that go into Module 4 of your IND. The battery is built to cover the three kinds of genetic damage (gene mutation, structural chromosome damage, and numerical chromosome change) with the fewest assays that do the job. ICH S2(R1) gives you two acceptable options, and which one you pick is a real decision rather than a formality.

Option 1 is the classic in vitro pair plus an in vivo confirmation: a bacterial reverse mutation test (the Ames test, OECD 471) for gene mutation, an in vitro mammalian assay for chromosome damage (either the chromosomal aberration test, OECD 473, or the mouse lymphoma TK assay, OECD 490), and an in vivo test, usually the rodent bone marrow micronucleus (OECD 474), integrated into a repeat-dose tox study so you do not run a standalone animal study. Option 2 leans more on in vivo work, pairing the Ames test with two in vivo endpoints, typically a micronucleus assay plus a Comet assay (OECD 489) or a second tissue. The in vitro micronucleus test (OECD 487) is a common, flow-cytometry-friendly alternative to chromosomal aberration. A capable CRO will help you pick the combination that fits your modality, your exposure, and your tox study design.

On execution, the value of a good genotox lab shows up in the boring details: validated assay systems with current positive- and negative-control performance, the right metabolic activation (S9), solubility and cytotoxicity range-finding so the top dose is defensible, and clean handling of the awkward cases (a compound that is poorly soluble, colored, antibacterial, or that precipitates at high concentrations). Large biologics are usually exempt from the standard battery because a protein does not interact with DNA the way a small molecule does, so for an antibody or a peptide a strong CRO will tell you which assays are simply not warranted rather than billing for a default battery.

How do you choose a genetic toxicology CRO?

Score two or three labs against the same written scope, because genotox quotes are easy to make look different by quietly assuming a different battery, a different second in vitro assay, or whether the in vivo micronucleus is integrated into your tox study or run standalone. Pin the assay list (which OECD guidelines, GLP or non-GLP per assay, with or without S9) before you compare price, or you are comparing different studies.

The single most important filter is regulatory track record, not headline rate. A repeated study or a question on a positive result at IND review costs far more than the savings on a cheap quote.

• Quality and GxP status: confirm GLP compliance (21 CFR Part 58, or OECD GLP for ex-US work) per assay, ask for recent inspection history, and check that exploratory screens you do not intend to file are priced as non-GLP rather than at GLP rates.
• Capacity and lead time: in vitro assays (Ames, in vitro micronucleus or chromosomal aberration) turn around in weeks, but slot availability and report time, not bench time, are usually the binding constraint. Confirm the protocol-to-final-report timeline and what historically causes slippage.
• Modality and indication fit: a strong small-molecule genotox lab may not be the right partner for an oligonucleotide, an ADC payload, or a large protein. Confirm the lab knows when the standard battery applies, when an impurity-focused ICH M7 approach is needed, and when a biologic is exempt.
• Region and regulatory fit: make sure the battery and reports are written to ICH S2(R1) and accepted by the agencies you plan to file with (FDA, EMA, PMDA), and that GLP status matches the region.
• Data quality and interpretation: ask how they handle equivocal or positive results, whether the study director will help with mechanistic follow-up or a weight-of-evidence argument, and what their concurrent and historical control databases look like.
• IP and confidentiality: settle who holds the data and reports, how samples and results are transferred to you, and the confidentiality terms on a compound you may not want disclosed, before any work starts.